Without A Prescription

ACOMPLIA Generic Rimonabant

Home » Prescription Drugs 1 » ACOMPLIA Generic Rimonabant

Appetite suppressant Anti obesity drug. Acomplia is used complementary to diet and exercise to treat .obese or overweight patients who suffer from Type 2 diabetes and abnormal levels of fat in the bloodA single pill has been found to stop both food and cigarette cravings enough to help people quit smoking and lose weight and could also help curb other unhealthy urges. In one study the medicine helped people who were overweight drop an average of 20 pounds and in another doubled the chances that smokers would quit. Acomplia contains the active ingredient Rimonabant. It is a selective CB1 Endocannabinoid Receptor Antagonist.Acomplia works by blocking receptors of a substance called cannabinoid 1 which stimulates hunger and other cravings in the brain and is also present in fat tissue. Sanofi argues that Acomplia can also prevent the risk ofCardiovascular disease.Patients with large waist circumference (102 cm in men and 88 cm in women) will mostly benefit from taking the drug.ACOMPLIA« (rimonabant) approved as an adjunct to diet and exercise for the treatment of obese patients (BMI ≥ 30 kg/m2) or overweight patients (BMI > 27 kg/m2) with associated risk factors such as type 2 diabetes or dyslipidemia.Side Effects:Acomplia was said to be well tolerated in early tests. The only relatively common side effects were mild GI side effects and dizziness and these were said to be transient.

Buy ACOMPLIA Generic Rimonabant and other Prescription Drugs 1 products online at Medstore.

Buy Online at Medstore - Click Here!

About ACOMPLIA Generic Rimonabant:

Product Type: Prescription Drugs 1

ACOMPLIA ( Generic Rimonabant )

ACOMPLIA (Generic Rimonabant)

Generic Rimonabant

20mg 28 Tabs 20mg 56 Tabs Generic Rimonabant ACOMPLIA

View more Prescription Drugs 1

Previous Product  Next Product

Without A Prescription: Education on antibiotic prescribing in Quebec worked. Guidelines for Quebec doctors on proper antibiotic use led to a decline in these prescriptions in the province, while prescribing rose in other provinces, a new study suggests. The guidelines were published and disseminated to Quebec doctors and pharmacists in January 2005 due to worries about the overuse of antibiotics and partly as a response to an outbreak of Clostridium difficile infections. Antibiotic consumption per capita was already 23.3 per cent higher in Canada generally than in Quebec in 2004, the study showed. But in the year that followed publication of the guidelines, the number of outpatient antibiotic prescriptions in Quebec decreased 4.2 per cent, the study said, while increasing 6.5 per cent in other Canadian provinces. The trend persisted three years later.